Loading data for ONC — first visit, this takes a few seconds.

BeOne Medicines AG

NasdaqGS: ONC · Real-Time Price · USD
371.98
-2.49 (-0.66%)
At close: Aug 28, 2026, 8:00 PM
366.73
+0.00%
After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

BeOne Medicines AG (ONC) Stock Price, Analysis & Data

-0.66%

No data available

Bid346.74
Market Cap41.49B
Revenue (ttm)6.13B
Net Income (ttm)655.71M
0.50
5.59
65.6
35.66
P/B (ttm)8.01
P/S (ttm)6.77
Earnings DateNov 5, 2026
Ask360.25
Volume349,775
Avg. Volume (20D)356,920
Open369.77
Previous Close374.47
Day's Range365.14 - 372.73
52-Week Range253.95 - 385.22
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVA...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2016
Employees 12,000
Stock Exchange NasdaqGS
Ticker Symbol ONC
Full Company Profile

Financial Performance

In 2025, BeOne Medicines's revenue was 5.34B, an increase of 40.23% compared to the previous year's 3.81B. Earnings were 286.93M, a decrease of -144.5%.

Financial Statements

Earnings Surprise

BeOne Medicines has released their quarterly earnings on Aug 5, 2026:
  • Revenue of $1.71B misses estimates by $0, with 29.63% YoY growth.
  • EPS of 2.05 exceeds estimates by 0.42, with 144.05% YoY growth.
BeOne Medicines AG is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade





Page 1 of 2